The 45 patient phase II trial met its primary endpoint of response to Algrx 4975 in treating pain induced by wrist dorsiflexion (bending back). Participants were given either a single injection of Algrx 4975 or placebo and assessed four weeks after the treatment.
At week four, 64% of patients treated with the drug were considered “responders,” compared to 30% of patients treated with placebo. A responder was defined as having no or slight pain upon wrist dorsiflexion on a 0-4 scale.
For patients treated with the drug candidate, a statistically significant improvement in the responder analysis was maintained eight weeks after treatment compared to placebo, and the trend for Algrx 4975 patients to have lower pain scores was maintained from two to 12 weeks.
“Algrx 4975 is a highly-differentiated product that could fill an important unmet need for an efficacious, non-opioid, long-acting pain reliever,” stated James Huang, president of Corgentech.